Oncogene-driven LUAD, such as lung cancer harboring activating epidermal growth factor receptor (EGFR) mutations, is known to be fairly resistant to ICI therapy, which can be at least partially explained by the adenosine pathway. The gene discussed is EGFR; the disease is lung cancer.